Lipo-Mino-Mix-C: What It Is, Where to Get It Prescribed, and What It Costs

Lipo-Mino-Mix-C is not a peptide, and it is not a single molecule. It is a compounded mixture of three lipotropic nutrients — methionine, inositol and choline, the "MIC" on the label — with three B vitamins: pyridoxine (B6), thiamine (B1) and cyanocobalamin (B12). All six are substances the body already uses in ordinary metabolism, and all six are available in food. The pharmacy dissolves them together in a sterile 10 mL multi-dose vial to a physician's prescription.

That shapes how to read this page. A nutrient mix has to be broken into six questions with six different answers. Some of the six have decades of human evidence for a specific job; the combination, injected into people who are not deficient, has almost none.

"Lipo" is short for lipotropic. The word dates from 1930s animal nutrition research, when rats fed diets lacking choline accumulated fat in the liver and adding choline — and later methionine, which the body can route toward choline — prevented it. A lipotropic substance, in that original sense, is one that helps the liver move fat out rather than store it. "Mino" refers to the amino acid in the mix, and "MIC" is pharmacy shorthand for methionine, inositol and choline. The suffix designates the pharmacy's formulation, which here adds pyridoxine and thiamine alongside the B12.

The name describes the liver-fat biology the ingredients were first studied for. It does not describe a proven effect on body weight, and the two should not be confused.

It is not a weight-loss medication. Nothing in it acts on appetite, gastric emptying or energy expenditure the way a GLP-1 medication does, and no randomised trial has shown that it changes weight. It is not a stimulant; the "energy" prescribers describe is the correction of a B12 or B1 shortfall where one exists. It is not a hormone, a steroid, a growth-hormone secretagogue or a peptide. And it is not a substitute for the diet and activity a weight-management program rests on.

Methionine is one of the nine essential amino acids and the direct precursor of S-adenosylmethionine, the body's principal methyl-group donor. Methyl groups are needed to make phosphatidylcholine, the phospholipid that coats the particles the liver uses to export fat. A 2008 review in the Annual Review of Nutrition covers methionine metabolism in the liver, including animal work in which disrupted methionine handling leads to fat accumulation and the observation that the same enzymes are altered in human liver disease.

Inositol, mostly as myo-inositol, is built into cell-membrane phospholipids and into the second messengers that relay part of the insulin signal inside cells. Its place in a lipotropic mix comes from older animal work in which inositol-deficient diets produced fatty liver in some species, and from a more recent human literature — almost entirely oral, at gram-level daily doses — on inositol and insulin sensitivity in women with polycystic ovary syndrome.

Choline has the clearest lipotropic mechanism. It is required to make phosphatidylcholine, which is required to assemble very-low-density lipoprotein, the particle that carries triglyceride out of the liver. When choline is short, that assembly stalls and fat stays in the liver. A 2009 review in Nutrition Reviews sets out the biology and why choline is classed as an essential nutrient.

The three vitamins are not lipotropic in their own right; they are included because the pathways above depend on them. B12 is the cofactor for methionine synthase, which regenerates methionine from homocysteine. B6 is the cofactor for the enzymes that route homocysteine down the alternative transsulfuration pathway. B1 is the cofactor for the enzymes that move carbohydrate through the energy cycle. In a person deficient in any of the three, the relevant pathway slows; in a person who is replete, additional vitamin is excreted.

Every mechanism above describes what happens when a nutrient is missing. Choline deficiency causes fatty liver, and restoring choline resolves it. B12 deficiency causes anaemia and fatigue, and restoring B12 corrects them. That is a different claim from "more of the nutrient produces more of the effect in someone who already has enough," and the research supports the first claim far better than the second.

This is the strongest human evidence for any component, and it concerns deficiency. A 1995 study in Hepatology followed adults on long-term intravenous nutrition who had developed fatty liver; when intravenous choline was added to their feeding, the steatosis resolved. A 2007 study in the American Journal of Clinical Nutrition placed healthy adults on a choline-depleted diet under controlled conditions and reported that most developed fatty liver or muscle damage, which cleared when choline was restored. These studies show choline is essential and that its absence produces liver fat. They do not show that extra choline reduces liver fat, or body fat, in a person eating a normal diet.

B12 has the deepest clinical literature of the six. A 2013 clinical-practice review in the New England Journal of Medicine covers diagnosis and treatment of deficiency, which is common in older adults, in people on metformin or acid-suppressing medication, in vegans and in anyone with impaired absorption. Injected B12 corrects deficiency reliably. A 2005 Cochrane review reported that high-dose oral B12 was as effective as intramuscular injection at correcting deficiency in the trials available, so the injection route here is a matter of formulation rather than superior effect, except where absorption is genuinely impaired.

A 2017 meta-analysis of randomised controlled trials in Endocrine Connections pooled trials of oral myo-inositol in women with polycystic ovary syndrome and reported effects on insulin-related measures in that population. Two qualifications apply: the trials used oral inositol at gram-level daily doses, and the population was women with a specific endocrine condition. Neither maps onto an injected mix given three times a week to a general weight-management population, and no trial has tested that use.

This is the question most people arrive with, and the answer is short. There are no randomised controlled trials of lipotropic injections — this combination or any similar methionine–inositol–choline preparation — for weight loss or body composition in humans. A PubMed search for lipotropic injections and weight outcomes returns no such trial as of September 2026. The clinical use rests on the deficiency biology above, on the long history of these injections in weight-management clinics, and on prescriber experience. That is a thin basis for a weight claim, and this page does not make one.

Per component, because there is none for the combination:

• Choline: controlled human depletion and repletion studies, and intravenous repletion in patients on parenteral nutrition. Strong for deficiency; nothing for weight.
• Cyanocobalamin (B12): extensive human evidence for correcting deficiency, including randomised comparisons of oral and intramuscular routes. No trial shows benefit in people who are not deficient.
• Inositol: randomised trials of oral myo-inositol in women with PCOS. No injectable trials; no general-population weight trials.
• Methionine, pyridoxine and thiamine: well-characterised roles and deficiency states. No injectable trials for weight or energy in replete people.
• The six together, by injection: no randomised controlled trials in humans.

• That the injection reduces body weight or body fat in anyone. That trial has not been run.
• That it "supports fat metabolism" in a person whose nutrient status is already normal. The mechanisms are deficiency mechanisms.
• That injecting these nutrients does anything oral intake would not, except in people with impaired absorption of B12.
• An effect size or a timeline for any outcome. Timelines described by prescribers are clinical experience.
• Efficacy for any condition as an FDA-approved treatment. The compounded mix is not approved for anything.

Under section 503A, a state-licensed pharmacy may compound with a bulk substance that complies with an applicable United States Pharmacopeia or National Formulary monograph; that is a component of an FDA-approved drug product, where no monograph exists; or that appears on the FDA's 503A bulks list. Substances nominated for that list but not yet decided sit in one of three categories under the agency's interim policy: Category 1 (under evaluation, where FDA does not intend to take enforcement action), Category 2 (identified significant safety risks) and Category 3 (nominated without adequate support).

Cyanocobalamin, pyridoxine and thiamine are each the active ingredient of FDA-approved single-ingredient injections that have been on the market for decades. They can be compounded from bulk on that basis, and none of the three appears in any category of the 503A nominations list.

Choline chloride sits in Category 1 — "Bulk Drug Substances Under Evaluation" — on the FDA's 503A nominations list, updated 14 May 2026. That is the category in which the agency has said it does not intend to take enforcement action against compounding while the evaluation proceeds.

Methionine and inositol do not appear in any of the three categories on the same list; compounding of both proceeds under the monograph route rather than the bulks-list route.

None of the six is in Category 2. The May 2026 Category 2 list contains cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use — nothing found in this product. The FDA's 2026 actions on peptides — the April Category 2 removals and the July advisory committee votes — concern peptides only and touch nothing in this mix.

No component of Lipo-Mino-Mix-C is restricted. Three of the six exist as FDA-approved injections in their own right; the compounded six-in-one preparation is not one of them, and it is not FDA approved as a finished product — compounded medications never are. They are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products. See are peptides FDA approved; the same logic applies to compounded vitamins.

Injection-site soreness in the muscle is the commonest report. Cyanocobalamin can deepen the colour of urine, which is harmless. People who were B12- or B1-deficient sometimes describe a change in energy within days, because deficiency correction is fast; people who were not deficient generally describe nothing.

Where prescribers describe any change, it is usually the deficiency story again: less fatigue in someone whose B12 was low, steadier energy across the day. Nobody should expect the scale to move because of the injection itself. If weight is changing, it is the diet, activity or GLP-1 medication running alongside it.

There is no described cumulative effect. The nutrients are water-soluble or rapidly metabolised, so the injection has to be repeated to maintain any deficiency correction. Whether continuing makes sense is a question for the physician at each refill, and often bloodwork should decide it.

There is no withdrawal and no rebound. Anyone who was deficient will drift back toward deficiency over months unless the underlying cause — diet, absorption, a medication such as metformin — is addressed.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.8 mL is 80 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the six components are in fixed proportion, every dose delivers the same split; if a physician wants a different balance, the components are prescribed separately.

Unlike most products on this site, this one is directed into the muscle, not the fat layer — the conventional route for B-vitamin injections. The usual sites are the deltoid, the upper outer quadrant of the buttock and the outer thigh, rotated so the same spot is not used repeatedly. Needle length matters more for an intramuscular injection than a subcutaneous one; use what is supplied with your directions and ask before substituting anything.

A 10 mL vial at 0.8 mL per dose gives 12 doses. At the directed three times weekly, that is four weeks of dosing, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. B vitamins degrade with light and time and the vial is entered repeatedly, so keep it in its carton in the fridge and check the date before each dose.

Both are built on the same methionine–inositol–choline core with B12. Lipo-B stops there; Lipo-Mino-Mix-C adds pyridoxine and thiamine. Neither has trial evidence for weight, and the choice is a physician's judgement about whether the extra B vitamins are wanted, not a question of which is stronger.

Methylcobalamin is a single-ingredient B12 injection in the active form; the B12 in this mix is cyanocobalamin, which the body converts. For a documented B12 deficiency, a physician will usually prefer the single ingredient, and the Cochrane evidence that high-dose oral B12 corrects deficiency as well as injection applies to both.

They are not comparable. Semaglutide and tirzepatide are medications with large randomised controlled trials for weight; Lipo-Mino-Mix-C is a nutrient mix with none. A physician may include the mix alongside a GLP-1 program, but nobody should choose it instead of one expecting a similar result.